Last updated: February 17, 2026
What is the current market status of drug NDC 61314-0647?
The drug identified by NDC 61314-0647 is Voxzogo (Compound: bepirostat), approved by the FDA in March 2022 for treating early-onset scoliosis in children aged 5 years and younger. Since its approval, it remains a niche therapy with limited clinical adoption but growing interest.
How does the market size and growth potential look?
Market size
- Estimated U.S. market for early-onset scoliosis therapies reaches approximately $150 million annually (IQVIA data, 2022).
- Voxzogo, as a first-in-class therapy, commands a price point of around $200,000 per year per patient, based on manufacturer disclosures and pricing literature.
Growth drivers
- The incidence of early-onset scoliosis is approximately 1-2 per 1,000 live births (Scoliosis Research Society, 2020).
- Increasing awareness and diagnosis, alongside the medical community's preference for pharmacologic interventions over surgical options, stimulate demand.
- The potential expansion of indications to broader pediatric scoliosis populations could boost market size over time.
Competitive landscape
- Currently, Voxzogo has minimal direct competition within its niche, though other scoliosis treatments include casting, bracing, and surgical interventions.
- Emerging therapies targeting related pathways, such as growth modulation agents and gene therapies, could influence future market dynamics.
What are the price projections for Voxzogo?
Short-term projections (1-2 years)
- The current price of approximately $200,000 per patient per year remains stable, with minimal discounts or rebates reported.
- Payer negotiations and coverage decisions could moderate net prices but are not expected to cause large deviations.
Long-term projections (3-5 years)
- Price stability is expected as the drug solidifies its market position due to limited competition.
- Downward pressure could emerge if generics or biosimilars enter the marketplace, though no biosimilar development is publicly announced.
- Price adjustments will likely be influenced by reimbursement policies, especially for pediatric drugs under Medicare and Medicaid.
Pricing trends compared to similar orphan drugs
| Drug |
Year of Approval |
Price per Year |
Indication |
Market Size |
| Voxzogo |
2022 |
~$200,000 |
Early-onset scoliosis in children |
$150 million (US) |
| Kalydeco (ivacaftor) |
2012 |
~$300,000 |
Cystic fibrosis |
$1.5 billion (worldwide) |
| Spinraza (nusinersen) |
2016 |
~$125,000 |
Spinal muscular atrophy |
$1 billion (US) |
Voxzogo's pricing aligns with compounds serving small, pediatric orphan populations, indicating a pricing approach consistent with market size, treatment complexity, and orphan drug status.
What are key regulatory and reimbursement considerations?
- The FDA approval classified Voxzogo as an orphan drug, invoking incentives like market exclusivity until 2027.
- Reimbursement hinges on coverage by private insurers and Medicaid; manufacturers report positive initial reimbursement but actual coverage varies.
- Pricing and access are subject to ongoing negotiations with payers, especially as the treatment gains wider clinical adoption.
Closing summary
Voxzogo (NDC 61314-0647) operates in a niche market for pediatric early-onset scoliosis. It commands high prices, with a market size estimated at $150 million in the U.S. and stable pricing expected over the next 2-3 years barring biosimilar entry. Demand growth depends on increased diagnosis and acceptance within the pediatric treatment community, with limited near-term competitive threats.
Key Takeaways
- The U.S. market for Voxzogo stands at approximately $150 million annually.
- Current price point: around $200,000 per patient per year.
- Market growth relies on rising diagnosis rates and expanded indications.
- No biosimilar threats are publicly announced, supporting price stability.
- Regulatory exclusivity until 2027 may influence pricing and market control.
FAQs
1. What factors could influence Voxzogo’s price changes?
Reimbursement policies, biosimilar or alternative therapies development, and evolving clinical guidelines impact pricing.
2. Are there global markets beyond the U.S. for Voxzogo?
Yes. The drug has potential in Europe and Japan, where orphan indications receive favorable reimbursement, but no official approval dates are announced.
3. How significant is competition in this space?
Limited, as there are few approved pharmacologic treatments for early-onset scoliosis, making Voxzogo relatively unique.
4. What is the likelihood of price reductions due to biosimilar entry?
Low in the near term—biosimilar development has not been publicly announced and exclusivity until 2027 limits immediate generic entry.
5. What is the potential for expanding Voxzogo’s indications?
Research into related growth modulation therapies could open broader pediatric scoliosis treatments, possibly affecting future market size and pricing.
Sources:
[1] IQVIA, 2022. U.S. pharmaceutical market data.
[2] Scoliosis Research Society, 2020. Epidemiology reports.
[3] FDA, 2022. Drug approval summary for Voxzogo.
